



Biomarkers for Immune-Mediated Diseases

Guest Editor:

Prof. Dr. Marcos López-Hoyos

Immunology Department,
Hospital Universitario Marqués
de Valdecilla-IDIVAL, Facultad de
Medicina, Universidad Cantabria,
Santander, Spain

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editor

Dear Colleagues,

The term immune-mediated inflammatory disease (IMID) encompasses a heterogeneous group of chronic inflammatory-based diseases that are characterized by (1) an inappropriate and dysregulation of the immune response with the production of pro-inflammatory cytokines, (2) a chronic inflammatory damage whose phenotype depends on the affected organ, (3) shared susceptibility genes and risk factors that can justify the co-occurrence of several IMIDs in the same individual and the familial aggregation of multiple IMIDs, (4) comorbidities and common effects generated by a chronic inflammatory state, and (5) a common response to pharmacological agents with common therapeutic targets within the inflammatory pathway.

This Special Issue is aimed at collecting recent evidence from basic and translational research on the possible biomarkers of clinical utility in the study of IMIDs. Special attention will be paid to the use of biomarkers as potential companion diagnostics in IMIDs in which therapeutic intervention in the immune response is essential at every stage of the disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical
Physiology, Nuclear Medicine &
PET National University Hospital,
Rigshospitalet, University of
Copenhagen, Blegdamsvej 9, DK-
2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Contact Us

Diagnostics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diagnostics
diagnostics@mdpi.com
[X@diagnostic_mdpi](https://twitter.com/diagnostic_mdpi)